I-cell disease

I-cell disease
ICD-10	E77.0
ICD-9	272.7
OMIM	252500
DiseasesDB	29175
MeSH	D009081

WikiDoc Resources for I-cell disease
Articles
Most recent articles on I-cell disease Most cited articles on I-cell disease Review articles on I-cell disease Articles on I-cell disease in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on I-cell disease Images of I-cell disease Photos of I-cell disease Podcasts & MP3s on I-cell disease Videos on I-cell disease
Evidence Based Medicine
Cochrane Collaboration on I-cell disease Bandolier on I-cell disease TRIP on I-cell disease
Clinical Trials
Ongoing Trials on I-cell disease at Clinical Trials.gov Trial results on I-cell disease Clinical Trials on I-cell disease at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on I-cell disease NICE Guidance on I-cell disease NHS PRODIGY Guidance FDA on I-cell disease CDC on I-cell disease
Books
Books on I-cell disease
News
I-cell disease in the news Be alerted to news on I-cell disease News trends on I-cell disease
Commentary
Blogs on I-cell disease
Definitions
Definitions of I-cell disease
Patient Resources / Community
Patient resources on I-cell disease Discussion groups on I-cell disease Patient Handouts on I-cell disease Directions to Hospitals Treating I-cell disease Risk calculators and risk factors for I-cell disease
Healthcare Provider Resources
Symptoms of I-cell disease Causes & Risk Factors for I-cell disease Diagnostic studies for I-cell disease Treatment of I-cell disease
Continuing Medical Education (CME)
CME Programs on I-cell disease
International
I-cell disease en Espanol I-cell disease en Francais
Business
I-cell disease in the Marketplace Patents on I-cell disease
Experimental / Informatics
List of terms related to I-cell disease

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: mucolipidosis II; ML II

Overview

Inclusion-cell (I-cell) disease is so named because waste products, thought to include carbohydrates, lipids, and proteins, accumulate into masses known as inclusion bodies. When tissues are examined under a microscope, the detection of inclusion bodies often provides a diagnosis of the disease.

Pathophysiology

I-cell disease is caused by a defect in mannose phosphorylation of lysosomal enzymes. Without mannose-6-phosphate to target them to the lysosomes, the enzymes are transported from the endoplasmic reticulum to the extracellular space. It can be associate with GNPTA.

Diagnosis

ML II is a particularly severe form of ML that resembles one of the mucopolysaccharidoses called Hurler syndrome. Some physical signs, such as abnormal skeletal development, coarse facial features, and restricted joint movement, may be present at birth. Children with ML II usually have enlargement of certain organs, such as the liver or spleen, and sometimes even the heart valves. Affected children often fail to grow and develop in the first months of life. Delays in the development of their motor skills are usually more pronounced than delays in their cognitive (mental processing) skills. Children with ML II eventually develop a clouding on the cornea of their eyes and, because of their lack of growth, develop short-trunk dwarfism (underdeveloped trunk). These young patients are often plagued by recurrent respiratory tract infections, including pneumonia, otis media (middle ear infections), and bronchitis. Children with ML II generally die before their seventh year of life, often as a result of congestive heart failure or recurrent respiratory tract infections.

See also

• Mucolipidosis